ROCKVILLE, Md. and MONROVIA, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) and Xencor, Inc. today announced a collaboration agreement under which Xencor will apply its proprietary XmAb(TM) humanization and optimization technologies to enhance the pharmacologic properties of monoclonal antibodies developed by HGS that specifically target antigens discovered by HGS.
"The priority focus of HGS continues to be the rapid commercialization of our late-stage compounds - Albuferon(R) for hepatitis C, LymphoStat-B(R) for lupus, and ABthrax(TM) for inhalation anthrax. We also have an exciting mid- stage pipeline led by our oncology program," said H. Thomas Watkins, President and Chief Executive Officer, HGS. "Today's announcement demonstrates our continuing commitment to targeted innovation based on HGS discoveries and our extensive intellectual property estate. We look forward to working with Xencor to maximize the therapeutic potential of several important new HGS product candidates."
Under the terms of the agreement, Xencor will receive an upfront payment and is eligible to receive additional payments including development and commercial milestones, and royalties on any products commercialized under the agreement. HGS will be responsible for all preclinical and clinical development, manufacturing and commercialization. Financial terms were not disclosed.
"This collaboration further validates the breadth of our XmAb
technology platform," commented Bassil Dahiyat, Ph.D., President and CEO of
Xencor. "Our proprietary tools optimize the complet
|SOURCE Human Genome Sciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved